These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 37275876)

  • 1. PD-1/PD-L1 axis in organ fibrosis.
    Zhao Y; Qu Y; Hao C; Yao W
    Front Immunol; 2023; 14():1145682. PubMed ID: 37275876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
    Jiang A; Liu N; Wang J; Zheng X; Ren M; Zhang W; Yao Y
    Front Immunol; 2022; 13():1022228. PubMed ID: 36544757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for 
non-small cell lung cancer].
    Lin C; Chen X; Liu J; Huang Y; Ou-Yang X
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):734-40. PubMed ID: 25342040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
    Veluswamy P; Wacker M; Scherner M; Wippermann J
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes.
    Falcone M; Fousteri G
    Front Endocrinol (Lausanne); 2020; 11():569. PubMed ID: 32973682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
    Liang B; Hu X; Ding Y; Liu M
    J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory mechanisms of PD-1/PD-L1 in cancers.
    Lin X; Kang K; Chen P; Zeng Z; Li G; Xiong W; Yi M; Xiang B
    Mol Cancer; 2024 May; 23(1):108. PubMed ID: 38762484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
    Filippone A; Lanza M; Mannino D; Raciti G; Colarossi C; Sciacca D; Cuzzocrea S; Paterniti I
    Cancer Immunol Immunother; 2022 Sep; 71(9):2067-2075. PubMed ID: 35092481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis.
    Davis RJ; Lina I; Ding D; Engle EL; Taube J; Gelbard A; Hillel AT
    Laryngoscope; 2021 May; 131(5):967-974. PubMed ID: 32557663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases.
    Wang X; Wu M; Cao Y; Zhang Z; Guo F; Li X; Zhang Y
    Crit Rev Clin Lab Sci; 2019 Jan; 56(1):18-32. PubMed ID: 30602320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
    Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
    Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
    J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases.
    Salminen A
    J Mol Med (Berl); 2024 Jun; 102(6):733-750. PubMed ID: 38600305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.